Clinical Trial Update: Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating sorafenib in pediatric patients with relapsed or refractory solid tumors or leukemia; results completed with posted results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blastic Phase
• Childhood Acute Lymphoblastic Leukemia
• Childhood Acute Myeloid Leukemia
• Childhood Acute Promyelocytic Leukemia with Pml-rara
• Childhood Chronic Myelogenous Leukemia Bcr-abl1 Positive
• Juvenile Myelomonocytic Leukemia
• Philadelphia Chromosome Negative Bcr-abl1 Positive Chronic Myelogenous Leukemia

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-02